David Amsellem
Stock Analyst at Piper Sandler
(4.77)
# 111
Out of 4,974 analysts
152
Total ratings
64.17%
Success rate
23.22%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SUPN Supernus Pharmaceuticals | Maintains: Neutral | $36 → $40 | $46.01 | -13.06% | 16 | Aug 29, 2025 | |
| AMGN Amgen | Maintains: Overweight | $328 → $342 | $283.64 | +20.58% | 5 | Aug 25, 2025 | |
| BIIB Biogen | Maintains: Neutral | $115 → $118 | $140.67 | -16.12% | 2 | Aug 14, 2025 | |
| ABBV AbbVie | Assumes: Overweight | $231 | $212.56 | +8.68% | 1 | Aug 12, 2025 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $30 → $25 | $29.43 | -15.05% | 9 | Aug 8, 2025 | |
| CORT Corcept Therapeutics | Maintains: Overweight | $131 → $121 | $69.36 | +74.45% | 8 | Aug 1, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $154 → $175 | $144.10 | +21.44% | 11 | Jul 31, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $24 → $18 | $10.38 | +73.41% | 6 | May 15, 2025 | |
| COLL Collegium Pharmaceutical | Reiterates: Neutral | $36 → $37 | $38.37 | -3.57% | 8 | May 9, 2025 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $176 → $147 | $129.50 | +13.51% | 14 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $65 | $47.14 | +37.89% | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3 → $4 | $7.85 | -49.04% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $13 | $24.98 | -47.96% | 5 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $10 | $10.50 | -4.76% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $30 | $18.95 | +58.31% | 10 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $13 | $15.76 | -17.51% | 5 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $11 | $9.62 | +14.35% | 4 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $38 → $37 | $29.94 | +23.58% | 7 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $95.35 | -28.68% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $7.35 | -59.18% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $26.45 | +58.79% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $5.42 | +84.50% | 1 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $1.16 | +1,718.18% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $113 | $125.17 | -9.72% | 3 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $35.99 | +16.70% | 3 | Oct 16, 2023 |
Supernus Pharmaceuticals
Aug 29, 2025
Maintains: Neutral
Price Target: $36 → $40
Current: $46.01
Upside: -13.06%
Amgen
Aug 25, 2025
Maintains: Overweight
Price Target: $328 → $342
Current: $283.64
Upside: +20.58%
Biogen
Aug 14, 2025
Maintains: Neutral
Price Target: $115 → $118
Current: $140.67
Upside: -16.12%
AbbVie
Aug 12, 2025
Assumes: Overweight
Price Target: $231
Current: $212.56
Upside: +8.68%
Amphastar Pharmaceuticals
Aug 8, 2025
Maintains: Neutral
Price Target: $30 → $25
Current: $29.43
Upside: -15.05%
Corcept Therapeutics
Aug 1, 2025
Maintains: Overweight
Price Target: $131 → $121
Current: $69.36
Upside: +74.45%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Overweight
Price Target: $154 → $175
Current: $144.10
Upside: +21.44%
Organon & Co.
May 15, 2025
Maintains: Overweight
Price Target: $24 → $18
Current: $10.38
Upside: +73.41%
Collegium Pharmaceutical
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $38.37
Upside: -3.57%
Jazz Pharmaceuticals
May 7, 2025
Reiterates: Overweight
Price Target: $176 → $147
Current: $129.50
Upside: +13.51%
Apr 22, 2025
Initiates: Overweight
Price Target: $65
Current: $47.14
Upside: +37.89%
Mar 7, 2025
Reiterates: Neutral
Price Target: $3 → $4
Current: $7.85
Upside: -49.04%
Mar 6, 2025
Maintains: Overweight
Price Target: $16 → $13
Current: $24.98
Upside: -47.96%
Mar 5, 2025
Reiterates: Neutral
Price Target: $14 → $10
Current: $10.50
Upside: -4.76%
Jan 17, 2025
Maintains: Overweight
Price Target: $23 → $30
Current: $18.95
Upside: +58.31%
Jan 10, 2025
Maintains: Overweight
Price Target: $24 → $13
Current: $15.76
Upside: -17.51%
Nov 11, 2024
Maintains: Overweight
Price Target: $9 → $11
Current: $9.62
Upside: +14.35%
Oct 25, 2024
Reiterates: Overweight
Price Target: $38 → $37
Current: $29.94
Upside: +23.58%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $95.35
Upside: -28.68%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $7.35
Upside: -59.18%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $26.45
Upside: +58.79%
Apr 11, 2024
Initiates: Overweight
Price Target: $10
Current: $5.42
Upside: +84.50%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $1.16
Upside: +1,718.18%
Jan 16, 2024
Maintains: Overweight
Price Target: $90 → $113
Current: $125.17
Upside: -9.72%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $35.99
Upside: +16.70%